Drug intelligence / Profile preview

PD-Co-008

Development stage: Unknown
Lead developer: Chengdu Peide Biopharmaceutical
Modality: Recombinant Proteins and Enzymes

Overview

PD-Co-008 is an investigational cancer immunotherapy currently under development by **Chengdu Peide Biopharmaceutical**. The agent is a next-generation biologic, likely belonging to the company's portfolio of targeted cytokines or fusion proteins designed to enhance the immune system's ability to recognize and eliminate malignant cells. As of 2024, the program is in the late preclinical or Investigational New Drug (IND)-enabling stage, with an IND filing targeted for 2024 and the initiation of Phase I clinical trials projected for 2025. The specific molecular target and mechanism of action have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on PD-Co-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-Co-008.

Explore the full profile